ENMD Share Price

Open 1.73 Change Price %
High 1.74 1 Day 0.06 3.57
Low 1.70 1 Week 0.00 0.00
Close 1.74 1 Month 0.00 0.00
Volume 9506 1 Year 0.00 0.00
52 Week High 3.10
52 Week Low 1.06
ENMD Important Levels
Resistance 2 1.78
Resistance 1 1.76
Pivot 1.73
Support 1 1.72
Support 2 1.70
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

EntreMed, Inc. (NASDAQ: ENMD)

ENMD Technical Analysis 3
As on 13th Jun 2014 ENMD Share Price closed @ 1.74 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.82 & Sell for SHORT-TERM with Stoploss of 1.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
ENMD Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ENMD Other Details
Segment EQ
Market Capital 32179852.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.entremed.com
ENMD Address
ENMD
9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States
Phone: 240-864-2600
Fax: 301-315-2437
ENMD Latest News
Interactive Technical Analysis Chart EntreMed, Inc. ( ENMD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on EntreMed, Inc.
ENMD Business Profile
EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company. EntreMed's drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company�s other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis. ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases.